

### Progress towards achieving European Vaccine Action Plan goals, 2017

Goal	Indicator	Status	Goal	Indicator	Status
1	Sustain polio-free status <sup>a</sup> (Current risk)	Yes (Low)	4	Meets vaccination coverage targets DTP3 national immunization coverage ≥95% <sup>d</sup> ≥90% DTP3 coverage achieved in ≥90% of districts <sup>e</sup>	Yes Yes Yes
2	Measles elimination status <sup>b</sup>	Endemic	-	Make evidence-based decisions about introduction of new vaccines* <sup>e</sup>	No
	Rubella elimination status <sup>b</sup>	Eliminated	5	NITAG made a recommendation about PCV NITAG made a recommendation about RV NITAG made a recommendation about HPV	NN NN NN
3	Control hepatitis B infection <sup>c</sup>	Validation pending	6	Achieve financial sustainability of the national immunization programme** <sup>c</sup>	Yes

\*New vaccines introduced or not introduced based on NITAG evidence-based recommendations \*\*Country self-sufficient for procuring routine vaccines

### Demographic, income and health expenditure summary, 2017

Total Population <sup>f</sup>	143 989 754
Live births	1 806 754
Surviving infants	1 793 873
<5 years	9 527 025
<15 years	25 350 017
Neonatal mortality rate (per 1000 live births) <sup>f</sup>	3.3
Infant mortality rate (per 1000 live births) <sup>f</sup>	6.5
Number of districts <sup>e</sup>	ND
GNI (per capita, in USD) <sup>g</sup>	9220
Health spending as % of total government expenditure <sup>g</sup>	10



#### Immunization schedule, 2017<sup>e</sup>

Birth	BCG, HepB_Pediatric				
1M	HepB_Pediatric				
2M	PCV				
3M	DTwP, IPV				
4.5M	DT, DTwP, IPV, PCV				
6M	DTwP, DTwPHepB, HepB_Pediatric, OPV				
12M	Measles, MM, Mumps, Rubella				
15M	PCV				
18M	DTwP, OPV				
20M	OPV				
>5Y	aP				
6Y	Measles, MM, Mumps, Rubella				
6-7Y	Td				
7Y	BCG				
14Y	OPV, Td*				
*Repeats every 10 years					




	2013	2014	2015	2016	2017
BCG	96	96	96	96	95
HepB-BD	ND	ND	ND	ND	ND
DTP1	97	97	97	97	97
DTP3	97	97	97	97	97
НерВ3	97	97	97	97	97
Hib3	NR	NR	NR	NR	NR
Pol3	98	97	97	97	96
PCV3	NR	NR	ND	35	70
Rotac	NR	NR	NR	NR	NR
RCV1	98	98	98	98	98
MCV1	98	98	98	98	98
MCV2	97	97	97	97	97
	100		50		0 ND NR

### Vaccine coverage estimates, 2013-2017<sup>d</sup>

# Number of reported cases of vaccine-preventable diseases, 2013-2017<sup>e</sup>

	2013	2014	2015	2016	2017
Measles	2339	4711	843	178	721
Mumps	282	267	190	1106	4443
Rubella	233	72	25	38	5
Congenital rubella syndrome	0	0	1	0	0
Diphtheria	2	1	2	2	0
Tetanus	11	8	13	18	13
Pertussis	4510	4705	6452	8232	5411
Hepatitis A	8258	10 483	6429	6424	8059
Varicella	799 126	936 917	819 299	796 218	858 353

## Number of reported measles, mumps and rubella cases<sup>e</sup> and MCV coverage estimates<sup>d</sup>, 2013-2017




## Surveillance with laboratory confirmation of cases, 2017<sup>e</sup>


Measles	Yes
Rubella	Yes
Congenital rubella syndrome	Yes
Rotavirus	Yes
Invasive meningococcal disease	Yes
Invasive pneumococcal disease	Yes
Invasive Haemophilus influenzae disease	Yes

Note: Case-based surveillance (with laboratory confirmation of cases) assessed for measles, rubella, and congenital rubella syndrome. Hospital-based sentinel surveillance and/or population-based surveillance (both with laboratory confirmation of cases) assessed for rotavirus, invasive meningococcal disease, invasive pneumococcal disease, and invasive *Haemophilus influenzae* disease.

# Number of reported diphtheria, tetanus and pertussis cases<sup>e</sup> and DTP3 coverage estimates<sup>d</sup>, 2013-2017




#### **Reported target population, reported number of DTP3 doses administered and DTP3 reported coverage**<sup>e</sup>, **2013-2017**






# Percentage of districts by DTP3 reported coverage<sup>e</sup>, 2013-2017



### DTP1-DTP3 dropout rate, 2013-2017<sup>d</sup>



Note: Dropout rate is calculated using WUENIC


#### Immunization system characteristics, 2017

Sustained access to WHO accredited polio, measles, and rubella laboratories <sup>h</sup>	Yes	
NITAG in place that meets six WHO criteria <sup>e</sup>	No	
National system in place to monitor AEFIs <sup>e</sup>	Yes	
Communication plan in place to respond to vaccine safety-related events <sup>e</sup>		
Vaccine hesitancy assessment performed within last 5 years <sup>e</sup>		
Mandatory proof of immunization at school entry <sup>e</sup>		

Note: The six WHO NITAG criteria are 1. legislative or administrative basis for the advisory group; 2. formal written terms of reference; 3. at least five different areas of expertise represented among core members; 4. at least one meeting per year; 5. circulation of the agenda and background documents at least one week prior to meetings; 6. mandatory disclosure of any conflict of interest

### Vaccine stockouts by administrative level<sup>e</sup>, 2013-2017

	2013	2014	2015	2016	2017
BCG	No	No	No	No	No
DTP	No	No	No	No	No
НерВ	No	No	No	No	No
Hib	No	No	No	No	No
Pneumo	ND	Both	No	No	No
Rota	NR	NR	NR	NR	NR
OPV	No	No	No	No	No
IPV	No	No	No	No	No
Measles	No	No	No	No	No
HPV	*	*	*	NR	NR
TT	No	No	No	No	No



\*Data on HPV stockouts have only been collected in JRF since 2016



#### **Abbreviations**

AEFI	Adverse event following immunization	MCV1	measles-mumps-rubella vaccine, first dose
BCG	Bacille Calmette-Guerin vaccine for tuberculosis	MCV2	measles-mumps-rubella vaccine, second dose
CRS	congenital Rubella Syndrome	MMR	measles-mumps-rubella vaccine
DT	diptheria-tetanus-containing vaccine	ND	Data not available
DTP	diptheria-tetanus-pertussis-containing vaccine	NITAG	National Immunization Technical Advisory Group
DTP1	diphtheria-tetanus-pertussis-containing vaccine, first dose	NN	No NITAG
DTP3	diphtheria-tetanus-pertussis-containing vaccine, third dose	NR	Not relevant as vaccine not included in immunization schedule
GNI	Gross national income	OPV	oral polio vaccine
НерВ	hepatitis B	PCV	pneumococcal conjugate vaccine
НерВ3	hepatitis B vaccine, third dose	PCV3	pneumococcal conjugate vaccine, third dose
HepB-BD	hepatitis B vaccine, birth dose	Pol3	polio-containing vaccine, third dose
Hib	Haemophilus influenzae type b	RCV1	rubella-containing vaccine, first dose
Hib3	Haemophilus influenzae type b vaccine, third dose	Rotac	rotavirus vaccine-complete series
HPV	human papillomavirus	Td	tetanus-diphtheria-containing vaccine
IPV	inactivated polio vaccine	TT	tetanus toxoid vaccine
MCV	measles-containing vaccine	W,M,Y	Weeks, Months, Years

#### **Data sources**

- a European Regional Commission for Certification of Poliomyelitis eradication (RCC) meeting report: www.euro.who.int/32ndRCC
- b European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thRVC
- c European Vaccine Action Plan 2015-2020 Midterm report
- d WHO/UNICEF Estimates of National Immunization Coverage (WUENIC): (http://www.who.int/immunization/monitoring\_surveillance/data/en/)
- e WHO/UNICEF Joint Reporting Form on immunization (JRF)
- f World Population Prospects: The 2017 Revision, New York, United Nations
- g World Bank, World Development Indicators
- h Polio Laboratory Network: www.euro.who.int/poliolabnetwork & Personal communication based on annual accreditation process of the European Measles and Rubella Laboratory Network